Related Experiment Video

Updated: Nov 29, 2025

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.3K

Interventions on patent ductus arteriosus and its impact on congenital heart disease

Mariam Zaidi1, Nilofer Sorathia2, Hannah Abbasi2

  • 1Charing Cross Hospital, Imperial College London, London, UK.

Cardiology in the Young
|November 23, 2020
PubMed

Insights

Keeping the ductus arteriosus (DA) open is vital for some newborns. Stenting the PDA and Blalock-Taussig shunting are options, with stenting showing reduced morbidity and faster recovery.

Area of Science:

  • Cardiology
  • Neonatal Medicine
  • Pediatric Surgery

Background:

  • The ductus arteriosus (DA) is a fetal blood vessel connecting the pulmonary artery to the aorta, bypassing pulmonary circulation.
  • Normally, the DA closes shortly after birth due to increased oxygen levels and pulmonary resistance.
  • In certain congenital heart defects, DA patency is essential for survival.

Purpose of the Study:

  • To review management strategies for maintaining ductus arteriosus patency.
  • To compare the efficacy and outcomes of stenting versus shunting for duct-dependent lesions.

Main Methods:

  • Review of medical literature and multicenter trial data comparing PDA stenting and modified Blalock-Taussig shunting.
  • Analysis of mortality, morbidity, recovery times, and quality of life.

Main Results:

  • Both PDA stenting and shunting achieve similar mortality endpoints.
  • Stenting demonstrates significantly reduced morbidity compared to shunting.
  • Stenting is associated with shorter recovery, less need for ECMO, and improved quality of life.

Conclusions:

  • PDA stenting is a favorable option for maintaining ductus arteriosus patency in duct-dependent cardiac defects.
  • While effective, stent longevity remains a consideration for long-term management.

Keywords:
Surgeryaortaaortic dissectiondissection

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.0K
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.9K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
147
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
192
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
124
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
133
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
141
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
229